Efficacy of dehydroepiandrosterone to overcome the effect of ovarian ageing (DITTO): a proof of principle randomised controlled trial protocol

Kannamannadiar Jayaprakasan, Amarin Narkwichean, Walid E Maalouf, Bruce K Campbell, Kannamannadiar Jayaprakasan, Amarin Narkwichean, Walid E Maalouf, Bruce K Campbell

Abstract

Introduction: Dehydroepiandrosterone (DHEA) has been proposed to improve pregnancy rates in women with diminished ovarian reserve undergoing in vitro fertilisation (IVF) treatment. However, evidence regarding its efficacy is supported by a limited number of randomised controlled trials (RCTs). This double-blinded RCT aims to measure the effect of DHEA supplementation prior to and during controlled ovarian hyperstimulation on ovarian response prior to IVF treatment in women predicted to have poor ovarian reserve.

Methods and analysis: Sixty women with ovarian antral follicle count ≤10 and serum anti-Mullerian hormone ≤5 pmol/L undergoing IVF/intracytoplasmic sperm injection (ICSI) treatment at the Nurture fertility clinic, Nottingham will be recruited. They will be randomised to either receive DHEA capsule 75 mg/day or placebo for at least 12 weeks before egg collection. All participants will undergo standard long down regulation protocol using human menopausal gonadotropin 300 IU/day. Serum samples and follicular fluids at the time of egg collection will be collected for hormonal immunoassays. For ICSI participants, cumulus cells stripped from oocyte will be collected for cumulus gene expression analyses regarding oocyte competence. Microdrops of oocyte culture media before the time of ICSI will be assessed for glucose, pyruvate and lactate utilisation. Embryo transfer will be performed on day 2, 3 or 5 based on the number and quality of the embryos available. Pregnancy will be defined as urine pregnancy test positive (biochemical pregnancy) and 6-8 weeks ultrasound scan with fetal heart beat (clinical pregnancy) and live birth. It is planned to perform the molecular and nutritional fingerprint analyses in batches after finishing the clinical phase of the study.

Ethics and dissemination: The approval of the study was granted by the NHS Research Ethics Committee (Ref number NRES 12/EM/0002), the Medicines and Healthcare products Regulatory Agency (MHRA), and the Nottingham University Hospitals Trust Research and Development department. All participants shall provide written informed consent before being randomised into allocated treatment groups.

Trial registration number: Protocol V.2.0; EudraCT number: 2011-002425-21; http://www.clinicaltrials.gov; NCT01572025; CTA reference: 03057/0053/001-0002.

Keywords: GYNAECOLOGY.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Figures

Figure 1
Figure 1
Participant flow diagram (IVF, in vitro fertilization; ICSI, intracytoplasmic sperm injection; DHEA, dehydroepiandrosterone).
Figure 2
Figure 2
IVF/ICSI treatment protocol used in the study (IVF, in vitro fertilization; ICSI, intracytoplasmic sperm injection; DHEA, dehydroepiandrosterone; hCG, human chorionic gonadotropin).

References

    1. Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev 2009;30:465–93
    1. Office for National Statistics. Chapter 2: Household and families. In: Self A and Zealey L, Social Trends No 38. Palgrave Macmillan, Hampshire, 2008:15–28.
    1. Broekmans FJ, Kwee J, Hendriks DJ, et al. . A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 2006;12:685–718
    1. Broekmans FJ, Faddy MJ, Scheffer G, et al. . Antral follicle counts are related to age at natural fertility loss and age at menopause. Menopause 2004;11:607–14
    1. Santoro N, Isaac B, Neal-Perry G, et al. . Impaired folliculogenesis and ovulation in older reproductive aged women. J Clin Endocrinol Metab 2003;88:5502–9
    1. Soules MR, Sherman S, Parrott E, et al. . Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril 2001;76:874–8
    1. Templeton A, Morris JK, Parslow W. Factors that affect outcome of in-vitro fertilisation treatment. Lancet 1996;348:1402–6
    1. Menken J, Trussell J, Larsen U. Age and infertility. Science 1986;233:1389–94
    1. Trout SW, Seifer DB. Do women with unexplained recurrent pregnancy loss have higher day 3 serum FSH and estradiol values? Fertil Steril 2000;74:335–7
    1. Gleicher N, Weghofer A, Barad DH. Defining ovarian reserve to better understand ovarian aging. Reprod Biol Endocrinol 2011; 9:23.
    1. Freeman SB, Yang Q, Allran K, et al. . Women with a reduced ovarian complement may have an increased risk for a child with Down syndrome. Am J Hum Genet 2000;66:1680–3
    1. Warburton D. Biological aging and the etiology of aneuploidy. Cytogenet Genome Res 2005;111:266–72
    1. Hodges CA, Ilagan A, Jennings D, et al. . Experimental evidence that changes in oocyte growth influence meiotic chromosome segregation. Hum Reprod 2002;17:1171–80
    1. Nejat EJ, Chervenak JL. The continuum of ovarian aging and clinicopathologies associated with the menopausal transition. Maturitas 2010;66:187–90
    1. Traub ML, Santoro N. Reproductive aging and its consequences for general health. Ann N Y Acad Sci 2010;1204:179–87
    1. Fitzpatrick LA, Litin SC, Bell MR. The Women's Health Initiative: a heart-to-HRT conversation. Mayo Clin Proc 2000;75:559–61
    1. Li H, Simpson ER, Liu JP. Oestrogen, telomerase, ovarian ageing and cancer. Clin Exp Pharmacol Physiol 2010;37:78–82
    1. Hansen KR, Knowlton NS, Thyer AC, et al. . A new model of reproductive aging: the decline in ovarian non-growing follicle number from birth to menopause. Hum Reprod 2008;23:699–708
    1. de Bruin JP, Bovenhuis H, van Noord PA, et al. . The role of genetic factors in age at natural menopause. Hum Reprod 2001;16:2014–18
    1. Casson PR, Lindsay MS, Pisarska MD, et al. . Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum Reprod 2000;15:2129–32
    1. Gleicher N, Weghofer A, Barad DH. Improvement in diminished ovarian reserve after dehydroepiandrosterone supplementation. Reprod Biomed Online 2010;21:360–5
    1. Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod 2006;21:2845–9
    1. Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet 2007;24:629–34
    1. Barad DH, Gleicher N. Increased oocyte production after treatment with dehydroepiandrosterone. Fertil Steril 2005;84:756.
    1. Sönmezer M, Ozmen B, Cil AP, et al. . Dehydroepiandrosterone supplementation improves ovarian response and cycle outcome in poor responders. Reprod Biomed Online 2009;19:508–13
    1. Wiser A, Gonen O, Ghetler Y, et al. . Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum Reprod 2010;25:2496–500
    1. Gleicher N, Barad DH. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod Biol Endocrinol 2011;9:67.
    1. Yeung TW, Chai J, Li RH, et al. . A randomized, controlled, pilot trial on the effect of dehydroepiandrosterone on ovarian response markers, ovarian response, and in vitro fertilization outcomes in poor responders. Fertil Steril 2014;102:108–15.e1
    1. Kara M, Aydin T, Aran T, et al. . Does dehydroepiandrosterone supplementation really affect IVF-ICSI outcome in women with poor ovarian reserve? Eur J Obstet Gynecol Reprod Biol 2014;173:63–5
    1. Narkwichean A, Maalouf W, Campbell BK, et al. . Efficacy of dehydroepiandrosterone to improve ovarian response in women with diminished ovarian reserve: a meta-analysis. Reprod Biol Endocrinol 2013;11:44.
    1. Jayaprakasan K, Campbell B, Hopkisson J, et al. . A prospective, comparative analysis of anti-Mullerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril 2010;93:855–64
    1. Jayaprakasan K, Chan Y, Islam R, et al. . Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women. Fertil Steril 2012;98:657–63
    1. Jayaprakasan K, Al-Hasie H, Jayaprakasan R, et al. . The three-dimensional ultrasonographic ovarian vascularity of women developing poor ovarian response during assisted reproduction treatment and its predictive value. Fertil Steril 2009;92:1862–9
    1. Nelson SM, Yates RW, Lyall H, et al. . Anti-Mullerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009;24:867–75
    1. Panjari M, Davis SR. DHEA therapy for women: effect on sexual function and wellbeing. Hum Reprod Update 2007;13:239–48

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner